AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34903116
Drug: Non-fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fluoridated milk (non-F-milk) adjunctive to 1000-ppm fluoride dentifrice (FD)
Trial: 32959604
Drug: TB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB treatment under BRAC program
Trial: 32212418
Drug: IV relebactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV relebactam 1150 mg
Trial: 33561904
Drug: Virgin olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin olive oil enriched with its own phenolic compounds (FVOO)
Trial: 33561904
Drug: Virgin olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin olive oil enriched with additional phenolic compounds from thyme (FVOOT)
Trial: 32581088
Drug: Rituximab (4×375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen, reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months)
Trial: 35340062
Drug: Risedronate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate daily
Trial: 32052026
Drug: Bifenthrin barrier
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin barrier spray and larval habitat management (LHM)
Trial: 32052026
Drug: Bifenthrin barrier
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin barrier spray alone
Trial: 32954647
Drug: Qishen Yiqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi dripping pills (QSYQ)
Trial: 32506278
Drug: Systemic erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic erythropoietin (10,000 units twice a day for 3 days)
Trial: 32506278
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (prednisone 75 mg daily tapered off in 6 weeks)
Trial: 36050629
Drug: US-guided internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided internal superior laryngeal nerve block with 2 ml of 0.25% ropivacaine bilaterally immediately after operation
Trial: 34182375
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (BAC = 0 g/l)
Trial: 37369125
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg/day for 1 week
Trial: 33318373
Drug: 10-kHz High-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-kHz High-frequency Therapy (HF10 Therapy)
Trial: 32885341
Drug: SRP followed
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP followed by laser therapy of the periodontal pockets with 980 nm diode laser, 1 W, continuous wave mode, 20 s per tooth side, repeated twice at 5–7 day intervals.
Trial: 34105614
Drug: Orofacial myofunctional
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orofacial myofunctional therapy associated with photobiomodulation
Trial: 34105614
Drug: Orofacial myofunctional
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orofacial myofunctional therapy associated with inactive photobiomodulation (placebo)
Trial: 36746160
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg twice daily)
Trial: 35843287
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE (Arm A)
Trial: 35843287
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE + 2 L of polyethylene glycol (PEG) 12 hours before CE (Arm B)
Trial: 35843287
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE + 1 L PEG + sodium ascorbate 3 hours before CE (Arm C)
Trial: 33006767
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) - mometasone furoate 0.1% ointment + dummy NB‐UVB
Trial: 33006767
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment - TCS + NB‐UVB
Trial: 34401368
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioral therapy for insomnia (iCBT-i)
Trial: 36028858
Drug: Givosiran (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givosiran (2.5 mg/kg monthly)
Trial: 36167599
Drug: Degarelix (240-80-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (240-80-80 mg) + Apalutamide (240 mg/d) for 3 months
Trial: 33938653
Drug: anterior QLB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anterior QLB (n=25) with preoperative ropivacaine 3.75 mg/mL, 20 mL bilaterally
Trial: 33938653
Drug: placebo QLB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo QLB (n=22) with preoperative isotonic saline, 20 mL bilaterally
Trial: 33938653
Drug: controls (n=23)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: controls (n=23) given only standard intravenous and oral analgesia
Trial: 35704475
Drug: ASC-enriched fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC-enriched fat grafting (10 × 10^6 ASCs/mL fat graft)
Trial: 33408315
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin once daily
Trial: 33408315
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rosuvastatin once daily
Trial: 33715955
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (80 mL)
Trial: 33715955
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (80 mL, placebo)
Trial: 32787879
Drug: n-3PUFA supplementation
RxNorm normalized name: (+/-)-N-methylephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3PUFA supplementation (3.3 g/day)
Trial: 32787879
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil placebo (PLA) (3.0 g/day)
Trial: 32424499
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment only group (Group 1)
Trial: 36166771
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for 90 days
Trial: 33159533
Drug: Home-based impact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based impact exercise intervention (16 weeks, progressively increasing to 50 multi-directional unilateral hops on each leg daily)
Trial: 36201325
Drug: GAL (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL (0.4 g.min‐1)
Trial: 36201325
Drug: GAL+GLU (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL+GLU (0.4 g.min‐1 galactose and 0.8 g.min‐1 glucose)
Trial: 36201325
Drug: GLU (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU (0.8 g.min‐1)
Trial: 35881895
Drug: SP16 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP16 (0.2 mg/kg)
Trial: 33956804
Drug: SP16 (0.0125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP16 (0.0125 mg/kg and 0.05 mg/kg)
Trial: 35507955
Drug: Momordica charantia
RxNorm normalized name: MOMORDICA CHARANTIA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momordica charantia (MC) 2000 mg/day for 12 weeks
Trial: 32377302
Drug: Plasma selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma selenium concentrations in MetS group (93.88 μg/L)
Trial: 32377302
Drug: Quartile 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile 1 (<82.36 μg/L)
Trial: 32377302
Drug: Quartile 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile 2 (82.37-92.66 μg/L)
Trial: 32377302
Drug: Quartile 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile 3 (92.67-103.52 μg/L)
Trial: 32588788
Drug: Hemospray therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemospray therapy
Trial: 33075037
Drug: Decision rule-guided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decision rule-guided antibiotic prescription (n = 402)
Trial: 32196636
Drug: Structured physical
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured physical activity (PA) intervention including two center-based plus three to four home-based exercise sessions per week, aiming for 150 minutes of walking weekly for 2.5 years on average
Trial: 33183320
Drug: BUDCA (berberine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUDCA (berberine ursodeoxycholate) at a dose of 2000 mg per day for 28 days
Trial: 35428650
Drug: Treg therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg therapy (TR001)
Trial: 33998561
Drug: Purposeful activity-based
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purposeful activity-based electrical stimulation therapy (PA‐EST) for 3 months (phase 1)
Trial: 33215554
Drug: Internet-Delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Delivered Cognitive Behavioral Therapy (Living with Deadly Thoughts)
Trial: 33306414
Drug: RRx-001 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRx-001 (4 mg once weekly until progression)
Trial: 33306414
Drug: Etoposide platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide platinum (EP) chemotherapy (etoposide 100 mg/m2 IV on days 1-3, cisplatin 80 mg/m2 IV on day 1 or carboplatin AUC 5-6 IV on day 1)
Trial: 34999207
Drug: Vascepa 2
RxNorm normalized name: Vascepa
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vascepa 2 g twice daily
Trial: 34999207
Drug: Fenofibrate in
RxNorm normalized name: Product containing fenofibrate in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate in patients with baseline triglycerides <250 mg/dL
Trial: 34999207
Drug: Fenofibrate in
RxNorm normalized name: Product containing fenofibrate in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate in patients with baseline triglycerides ≥250 mg/dL
Trial: 35751891
Drug: Kundur (Boswellia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kundur (Boswellia serrata) 1g vaginal insert daily for 21 days
Trial: 35751891
Drug: Miconazole (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole (2% w/w) 100mg vaginal suppository daily for 7 days
Trial: 34491649
Drug: Bo's abdominal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bo's abdominal acupuncture (combined with methotrexate treatment)
Trial: 34491649
Drug: Methotrexate tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets (5 mg once a week)
Trial: 35842108
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with paroxetine or venlafaxine extended release
Trial: 35842108
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PE and medication
Trial: 35918624
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg every 8 hours (control group)
Trial: 35918624
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg at breakfast and lunch, placebo at dinner (experimental group)
Trial: 35643520
Drug: Ma’s bamboo‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ma’s bamboo‐based medicinal moxibustion therapy
Trial: 32133778
Drug: Triprolidine 2.5
RxNorm normalized name: triprolidine 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 2.5 mg + Pseudoephedrine 60 mg
Trial: 36472675
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment involving 10–12 sessions attended by the mother and an identified family member (father) at each session.
Trial: 34882193
Drug: Fixed orthodontic
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed orthodontic treatment after periodontal stabilization
Trial: 36422809
Drug: DWP16001 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 (2 mg) + Metformin (1000 mg bid for 7 days)
Trial: 36422809
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg bid for 7 days)
Trial: 32100719
Drug: Subcutaneous collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous collagen injection (Group A, n = 10)
Trial: 32100719
Drug: Periradicular collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periradicular collagen injection (Group B, n = 10)
Trial: 32100719
Drug: Epidural collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural collagen injection (Group C, n = 10)
Trial: 616062701
Drug: Mitosis Kinase
RxNorm normalized name: Kinase (enzyme-activating), uro-urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitosis Kinase Score (MKS) before treatment
Trial: 616062701
Drug: Mitosis Kinase
RxNorm normalized name: Kinase (enzyme-activating), uro-urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitosis Kinase Score (MKS) in paired samples after treatment
Trial: 616062701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MKS and p21 expression
Trial: 35171317
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g meropenem, 3-h infusion
Trial: 35171317
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g meropenem, 3-h infusion
Trial: 35171317
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g meropenem, 6-h infusion
Trial: 32418546
Drug: (-)-OSU6162 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (-)-OSU6162 treatment
Trial: 33302116
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day elemental calcium
Trial: 35817581
Drug: Individualised feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised feedback on potentially inappropriate prescribing (PIP) of bronchodilator inhalers; feedback included visualised medication histories and action-oriented messages, sent in July 2015, February 2016, and August 2016.
Trial: 33397667
Drug: STRIDE intervention
RxNorm normalized name: Stridex
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRIDE intervention (6 weekly 1-hour sessions via videoconferencing)
Trial: 33397667
Drug: Medication monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitoring control group (electronic pill bottle and usual oncology care)
Trial: 38458208
Drug: Paracetamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol plus ibuprofen
Trial: 32994371
Drug: Shuxuetong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuetong injection
Trial: 35779553
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase (0.25 mg/kg to a maximum of 25 mg)
Trial: 35779553
Drug: Alteplase (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (0.9 mg/kg to a maximum of 90 mg; 0.09 mg/kg as a bolus and then a 60 min infusion of the remaining 0.81 mg/kg)
Trial: 34871098
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg QD
Trial: 34871098
Drug: Delpazolid 400
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 400 mg BID
Trial: 34871098
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg BID
Trial: 34871098
Drug: Delpazolid 1200
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 1200 mg QD
Trial: 34871098
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg BID
Trial: 36228639
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg twice daily for 3 days and then 0.6 mg once daily for 25 days
Trial: 36228639
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once daily for 28 days
Trial: 36228639
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (Control for aspirin)
Trial: 34628831
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral prednisone once a day for 14 days (Group A)
Trial: 34628831
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg oral prednisone once a day for 14 days (Group B)
Trial: 34628831
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral prednisone once a day for 14 days (Group C)
Trial: 35152882
Drug: Endoscopic retrograde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic retrograde appendicitis therapy (ERAT)
Trial: 39139457
Drug: D-penicillamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine therapy
Trial: 34285165
Drug: 1.9 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 µg HA/AS03B
Trial: 34285165
Drug: 0.9 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 µg HA/AS03C
Trial: 34285165
Drug: 1.9 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 µg HA/AS03C
Trial: 34285165
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg HA/AS03C
Trial: 34285165
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg HA/AS03D
Trial: 33927696
Drug: Stepwise reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise reduction of 12.5 IU rec-FSH daily in the Study group (SG)
Trial: 32470022
Drug: High H2
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High H2 water (containing 7 ppm of H2: 3.5 mg H2 in 500-mL water)
Trial: 34060416
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine paste, administered once weekly for eight consecutive weeks
Trial: 615916148
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral supplement containing 10mg lutein, 2mg zeaxanthin and 10mg meso-zeaxanthin for a period of 6 months
Trial: 32629007
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (COMPASS trial)
Trial: 32629007
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (IMRD-UK cohort)
Trial: 32152202
Drug: hu14.18‐IL2 immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18‐IL2 immunotherapy (Group A)
Trial: 32152202
Drug: hu14.18‐IL2 immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18‐IL2 immunotherapy (Group B)
Trial: 34845502
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg abiraterone with a low-fat meal (LOW)
Trial: 34845502
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg abiraterone fasting (STD)
Trial: 34895218
Drug: Fevipiprant 150
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fevipiprant 150 mg
Trial: 34895218
Drug: Fevipiprant 450
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fevipiprant 450 mg
Trial: 32706124
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma, 10-week protocol